PFI-90 is a selective inhibitor of histone demethylase (KDM3B) that inhibits PAX3-FOXO1 action. PFI-90 induces apoptosis and myogenic differentiation, resulting in the cell death increased. PFI-90 has the potential for the antitumor activity. (patent WO2021101929A1).
PFI-90 is a selective inhibitor of histone demethylase (KDM3B) that inhibits PAX3-FOXO1 action. PFI-90 induces apoptosis and myogenic differentiation, resulting in the cell death increased. PFI-90 has the potential for the antitumor activity. (patent WO2021101929A1).
PFI-90 shows dose response in RH4, RH30, OSA-CL and TC-32 cells, with IC50s of 812, 3200, 1895 and 1113 nM, respectively[1]. PFI-90 (3 μμ; 24 hours) increases apoptosis in RH4 and SCMC cells[1].
[1]. KHAN, Javed, et al. Inhibitors of histone demethylases (pfi-63 and pfi-90) for the treatment of cancer and for the inhibition of histone demethylase in cells. WO2021101929A1.
